Cell Based Assay & High Content Screening Market Research Report 2022: Find the Opportunities and Pitfalls & Understand Growth Expectations and the Ultimate Potential Market Size – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cell Based Assay & High Content Screening Markets. Market Forecasts by Application with Executive and Consultant Guides and including Customized Forecasting and Analysis.” report has been added to ResearchAndMarkets.com’s offering.

The report includes five year market forecasts.

Cell-Based Assays are a mainstay of drug development and scientific research, but growth is now accelerating as the race for a COVID-19 cure gains speed.

On top of this, new technology is allowing Cell-Based Assays to be used to measure any aspect of cell function. This market just keeps on growing with no end in sight. The workhorse of the pharmaceutical industry is becoming a central player in biotechnology.

This is a complex area but this readable report will bring the entire management team up to speed, on both the technology and the opportunity.

The technology is moving faster than the market. Genomics and Immunology are playing a role too. Find the opportunities and pitfalls. Understand growth expectations and the ultimate potential market size.

Key Topics Covered:

Market Guides

• Situation Analysis & COVID-19 Impact
• Guide for Executives and Marketing Staff
• Guide for Investment Analysts and Management Consultants

1. Introduction and Market Definition

1.1 What are Cell Based Assays?

1.2 Clinical Trial Failures

1.2.1 Immuno-oncology Plays a Leading Role in Cell Based Assays

1.2.2 Infectious Disease Will Play a Larger Role

1.3 Market Definition

1.3.1 Market Size

1.3.2 Currency

1.3.3 Years

1.4 Methodology

1.4.1 Authors

1.4.2 Sources

1.5 U.S. Medical Market and Pharmaceutical Research Spending – Perspective

1.5.1 U.S. Expenditures for Pharmaceutical Research

2. Cell Based Assays – Guide to Technology

2.1 Cell Cultures

2.1.1 Cell Lines

2.1.2 Primary Cells

2.1.3 Stem Cells

2.1.3.1 iPSC’s – The Special Case

2.2 Cell Assays

2.3 Cell Viability Assays

2.3 Cell Proliferation Assays

2.4 Cytotoxicity Assays

2.5 Cell Senescence Assays

2.6 Apoptosis

2.7 Autophagy

2.8 Necrosis

2.9 Oxidative Stress

2.10 2D vs. 3D

2.11 Signalling Pathways, GPCR

2.12 Immune Regulation & Inhibition

2.13 Reporter Gene Technology

2.14 CBA Design & Development

2.15 Cell Based Assays – The Takeaway

3. Industry Overview

3.1 Players in a Dynamic Market

3.1.1 Academic Research Lab

3.1.2 Contract Research Organization

3.1.3 Genomic Instrumentation Supplier

3.1.5 Cell Line and Reagent Supplier

3.1.6 Pharmaceutical Company

3.1.7 Audit Body

3.1.8 Certification Body

4. Market Trends

4.1 Factors Driving Growth

4.1.1 Candidate Growth

4.1.2 Immuno-oncology

4.1.3 Genomic Blizzard

4.1.4 Technology Convergence

4.1.5 The Insurance Effect

4.2 Factors Limiting Growth

4.2.1 CBA Development Challenges

4.2.2 Instrument Integration

4.2.3 Protocols

4.3 Technology Development

4.3.1 3D Assays

4.3.2 Automation

4.3.3 Software

4.3.4 Primary Cells

4.3.5 Signalling and Reporter Genes

4.3.6 The Next Five Years

5. Cell Based Assays Recent Developments

• Axxam and FUJIFILM Cellular Dynamics Announce Strategic Alliance
• Cancer Genetics to Acquire Organoid Startup Stemonix
• Curi Bio Acquires Artificial Intelligence Firm Dana Solutions
• CRISPR Screens Uncover Novel Cancer Therapy Targets
• ERS Genomics Licenses CRISPR-Cas9 Patents to Axxam
• New Transcriptomics Assay Facilitates Compound Screens
• Carta Biosciences Betting on Gene Interaction Mapping
• High-throughput Identifies cancer drug candidates
• Velabs Therapeutics partners with Alytas Therapeutics to develop a novel immune-based therapy for obesity
• InSphero platform selected to test Cyclerion’s sGC stimulator technology
• OcellO to provide in vitro research services to Merus
• Charles River Laboratories to acquire Citoxlab
• Reaction Biology Corporation Purchases ProQinase GmbH
• Cisbio extends its assay portfolio for immuno-oncology drug discovery
• STEMCELL Technologies Launches Next-Generation Culture System
• Abcam Acquires Calico Biolabs
• Evotec announces achievement in Celgene alliance utilizing IPSC
• screening
• Fujifilm Cellular Dynamics Inc. launches iCELL Microglia
• Cisbio and Excellerate Bioscience partner
• Horizon Discovery extends CRISPR Screening Service to primary human T cells

6. Profiles of Key Cell Based Assay Companies

• Abcam
• Agilent
• Aurora Instruments Ltd
• Axxam
• Beckman Coulter Diagnostics
• Becton, Dickinson and Company
• BioIVT
• Bio-Rad Laboratories, Inc.
• BioTek Instruments
• BioVision, Inc.
• BMG Labtech
• Cell Biolabs, Inc
• Cell Signaling Technology, Inc.
• Charles River Laboratories
• Cisbio Bioassays
• Corning, Inc
• Cytovale
• Enzo Life Sciences, Inc
• Eurofins DiscoverX Corporation
• Evotec AG
• Excellerate Bioscience
• Fujifilm Cellular Dynamics International
• Genedata
• Hemogenix
• Horizon Discovery
• Invivogen
• Leica Biosystems
• Lonza Group Ltd.
• Luminex Corp
• Merck & Co., Inc
• Miltenyi Biotec
• Molecular Devices
• Nanion
• Ncardia
• New England Biolabs, Inc
• Olympus
• Origene Technologies
• Perkin Elmer
• Promega
• Qiagen Gmbh
• Reaction Biology
• Recursion Pharma
• Roche Diagnostics
• Sartorius
• Sartorius-ForteBio
• Sartorius-IntelliCyt
• Sony Biotechnology
• SPT Labtech
• Stemcells Technologies Canada Inc
• Tecan
• Thermo Fisher Scientific Inc.
• Vitro Biopharma

For more information about this report visit https://www.researchandmarkets.com/r/wm6xr

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900